Anticoagulant Therapy

More on PTT Specimen Storage Time

On November 1 I replied to a question from Joe Lamb, Columbus, GA about room temperature storage of specimens for partial thromboplastin time (PTT) assays that are sent to reference laboratories. Joe was concerned that his reference lab claimed PTT results were valid on specimens less than 24 hours old, whereas the CLSI Guideline H21-A5 sets […]

Anticoagulant Therapy

Serotonin Release by Immunoassay?

Dear George, For heparin-induced thrombocytopenia (HIT) serotonin release assay, can serotonin ELISA sensitive to HIT be used? With regards, Vilas Hiremath. Hello, Vilas, always good to hear from you. I had to go to experts, Drs Larry Brace, Edward Hospital in Naperville IL, and Jon Geske, Precision BioLogic Manager of Emerging Technologies & Markets. Here is a reply […]

Anticoagulant Therapy

Fondaparinux Assay

Hi George! Would you happen to have a list of laboratories performing the anti-Xa assay for Fondaparinux (pentasaccharide, Arixtra)? Do you recommend, when calibrating the assay, to use commercially-available material or spiked normal pooled plasma (NPP)? Thanks for your help!! Love this resource that you provide!! Crystal Azevedo, MT(ASCP)SH Hi, Crystal, thanks for your comment. Machaon […]

Anticoagulant Therapy

Quick Question: Heparin Therapeutic Range

On October 21 I posted my

Anticoagulant Therapy

CAP Requires INR Reference Interval

From Dr. John Olson, University of Texas Medical Center in San Antonio: Hello George, Happy New Year! I hope that your holiday was as pleasant for you as mine was for me. I read with interest the brief piece on the reference interval for the INR. When I was at the University of Iowa a number of […]

Anticoagulant Therapy

Heparin Brill-Edwards Curve Calibrators?

Steve Duff, co-CEO of Precision BioLogic received this question from a subscriber: Has Precision ever considered producing a set of 30 plasmas containing varying levels of unfractionated heparin? I think there is a strong need for a commercial product that can be used to fulfill the CAP requirement for heparin therapeutic range development. It is […]

Anticoagulant Therapy

More on Oral Anticoagulants: Rivaroxaban

Here is a December 19 “FirstWord” post announcing EU clearance of rivaroxaban (Xarelto, Bayer) for stroke prevention and treatment of deep venous thrombosis. Thanks to Steve Duff, Precision BioLogic co-CEO for alerting me to this evidence of the 2011 march to the adoption of new oral anticoagulants.

Anticoagulant Therapy

New Oral Anticoagulants and HIT

An article posted December 15 on TheHeart.org quotes Dr. Jawed Fareed, Loyola University, Chicago, who demonstrated using an in vitro experiment that rivaroxaban, apixaban, and dabigatran do not interact with the anti-platelet factor 4 antibodies responsible for heparin-induced thrombocytopenia with thrombosis, a severe side effect of unfractionated heparin therapy. The findings were reported at this year’s American Society […]

Anticoagulant Therapy

Bad News About Dabigatran

Larry Brace, PhD, Edward Hospital in Naperville, IL, alerted me by telephone yesterday about the RE-LY study’s reported bleeding rate for the new oral anticoagulant, dabigatran (Pradaxa), which may be linked to using the 150 mg/day dosage. I’ve linked the story as it appears in TheHeart.org. Dr. Brace suggests on the basis of physiology that the anti-Xa anticoagulants […]

Anticoagulant Therapy

Dabigatran in the ER

Dave McGlasson sent me this HeartWire link describing the problems of Dabigatran in trauma situations. This looks like a new risk associated with the oral anticoagulant.

Anticoagulant Therapy

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question